science

Radotinib

Radotinib is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Radotinib rather than just read about it. In short: Radotinib (INN; trade name Supect), also known by its investigational code IY5511, is an oral Bcr-Abl tyrosine-kinase inhibitor used in the treatment of Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML). It was developed by Il-Yang Pharmaceutical Co., Ltd (South Korea) and is marketed domestically by Daewoong Pharmaceutical Co., Ltd.

Key takeaways

Radotinib belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Radotinib to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Radotinib from memory before moving on to harder problems.

Reference excerpt

Radotinib (INN; trade name Supect), also known by its investigational code IY5511, is an oral Bcr-Abl tyrosine-kinase inhibitor used in the treatment of Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML). It was developed by Il-Yang Pharmaceutical Co., Ltd (South Korea) and is marketed domestically by Daewoong Pharmaceutical Co., Ltd. Radotinib was approved in South Korea in 2012 for patients with resistance or intolerance to other tyrosine kinase inhibitors such as imatinib.

Medical uses Radotinib is indicated for the treatment of adult patients with Ph+ CML in the chronic phase who are resistant or intolerant to prior therapy with first-generation tyrosine kinase inhibitors such as imatinib. Its use remains limited to South Korea, where it is prescribed under the brand name Supect.

Mechanism of action Radotinib is a selective inhibitor of the Bcr-Abl tyrosine kinase, the abnormal fusion protein expressed in Ph+ CML. It also inhibits the platelet-derived growth factor receptor (PDGFR). By blocking Bcr-Abl–mediated signaling, radotinib suppresses proliferation of leukemic cells.

Clinical trials In 2011, Il-Yang initiated a Phase III, multinational, randomized study comparing radotinib with imatinib as first-line therapy in newly diagnosed Ph+ CML. A Phase II trial demonstrated efficacy and safety in patients resistant or intolerant to other Bcr-Abl inhibitors, with major cytogenetic response rates comparable to second-generation drugs such as nilotinib. Common adverse effects observed in clinical studies included hematologic toxicities (thrombocytopenia, neutropenia, anemia), gastrointestinal events, and elevations in liver transaminases.

Regulatory status Radotinib received regulatory approval in South Korea in 2012. As of 2025, it has not been approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

See also Imatinib Nilotinib Dasatinib Bcr-Abl tyrosine-kinase inhibitors

References

Illustrations

Worked examples

Example 1 — a first encounter with Radotinib

Start with the simplest possible case. Write down what Radotinib claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Radotinib before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Radotinib ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Radotinib

In research: Radotinib appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Radotinib in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Radotinib is common in secondary-school and first-year university syllabi. It links to neighbouring topics (Trifluoromethyl)benzene derivatives, Aminopyrimidines, Benzamides, so understanding it makes those chapters shorter.
In everyday life: Look for Radotinib outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Radotinib” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Radotinib in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Radotinib means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Radotinib out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Radotinib in simple terms?

Why does Radotinib matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Radotinib?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Radotinib.